Huakang Biomedical Holdings Past Earnings Performance

Past criteria checks 0/6

Huakang Biomedical Holdings's earnings have been declining at an average annual rate of -8.7%, while the Medical Equipment industry saw earnings growing at 10.9% annually. Revenues have been declining at an average rate of 0.6% per year.

Key information

-8.7%

Earnings growth rate

-7.4%

EPS growth rate

Medical Equipment Industry Growth	13.7%
Revenue growth rate	-0.6%
Return on equity	-11.3%
Net Margin	-23.5%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Huakang Biomedical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:8622 Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	25	-6	20	3
30 Sep 23	24	-5	19	3
30 Jun 23	25	-4	19	3
31 Mar 23	25	-3	19	3
31 Dec 22	25	-3	19	2
30 Sep 22	26	-2	18	3
30 Jun 22	26	-3	18	3
31 Mar 22	27	-4	18	3
31 Dec 21	26	-4	18	2
30 Sep 21	26	-7	18	2
30 Jun 21	27	-8	19	2
31 Mar 21	25	-10	21	2
31 Dec 20	22	-12	21	2
30 Sep 20	21	-9	21	2
30 Jun 20	21	-7	20	2
31 Mar 20	22	-3	18	2
31 Dec 19	25	0	16	2
30 Sep 19	26	-3	16	2
30 Jun 19	27	-2	14	2
31 Mar 19	28	0	12	1
31 Dec 18	29	0	11	1
31 Dec 17	27	-2	6	1
31 Dec 16	25	8	5	1
31 Dec 15	19	8	4	2

Quality Earnings: 8622 is currently unprofitable.

Growing Profit Margin: 8622 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 8622 is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare 8622's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8622 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8.2%).

Return on Equity

High ROE: 8622 has a negative Return on Equity (-11.33%), as it is currently unprofitable.

Huakang Biomedical Holdings Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

Recent updates

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta